Stacy Grieve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stacy Grieve has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Jing Hu
Division of Cancer Biology and Genetics, Queen's University
2 shared publications- Keith R. Brunt
Dalhousie University
2 shared publications - Peter A. Greer
Department of Pathology and Molecular Medicine, Queens University, Kingston, Ontario, Canada
2 shared publications - Tony Reiman
Department of Biological Sciences University of New Brunswick Saint John New Brunswick Canada
2 shared publications - Xiaolong Yang
Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada
2 shared publications A. Forsythe
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13
Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study
- 1 September 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13
Open AccessDevelopment and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study
- Open Access
- 16 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (6) , 110243
Quantification and structure–function analysis of calpain-1 and calpain-2 protease subunit interactions
- 16 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (6) , 110243
Open AccessQuantification and structure–function analysis of calpain-1 and calpain-2 protease subunit interactions
- Open Access
- 31 July 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (3) , 857-877
Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease
Background: Healing in Crohn’s disease is complex and difficult to measure due to incongruencies between clinical symptoms and disease states. Mucosal healing (MH) and transmural healing (TH) are increasingly used to measure clinical improvement in Crohn’s disease, but definitions of MH and TH can vary across studies, and their relationship to long-term outcomes is not clear. To address this knowledge gap, we performed a systematic literature review (SLR) to examine studies measuring MH and TH in Crohn’s disease. Methods: Database records from 2012 to 2022 were searched for real-world evidence and interventional studies that reported the association of MH or TH with clinical, economic, or quality of life outcomes of adult patients with Crohn’s disease. Results: A total of 46 studies were identified in the systematic literature review, representing a combined patient population of 5530. Outcomes of patients with MH were reported by 39 studies; of these, 14 used validated scales for endoscopic assessment. Thirteen studies reported outcomes of patients with TH. Among studies that examined the outcomes of patients with and without MH or TH, patients with healing generally experienced improved clinical outcomes and reduced healthcare resource utilization, including fewer hospitalizations and surgeries and improved rates of clinical remission. This was especially true for patients with TH. Conclusions: Mucosal and transmural healing are associated with positive long-term outcomes for adult patients with Crohn’s disease. The adoption of standardized measures and less invasive assessment tools will maximize the benefits of patient monitoring.
- 31 July 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (3) , 857-877
Open AccessMucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease
Background: Healing in Crohn’s disease is complex and difficult to measure due to incongruencies between clinical symptoms and disease states. Mucosal healing (MH) and transmural healing (TH) are increasingly used to measure clinical improvement in Crohn’s disease, but definitions of MH and TH can vary across studies, and their relationship to long-term outcomes is not clear. To address this knowledge gap, we performed a systematic literature review (SLR) to examine studies measuring MH and TH in Crohn’s disease. Methods: Database records from 2012 to 2022 were searched for real-world evidence and interventional studies that reported the association of MH or TH with clinical, economic, or quality of life outcomes of adult patients with Crohn’s disease. Results: A total of 46 studies were identified in the systematic literature review, representing a combined patient population of 5530. Outcomes of patients with MH were reported by 39 studies; of these, 14 used validated scales for endoscopic assessment. Thirteen studies reported outcomes of patients with TH. Among studies that examined the outcomes of patients with and without MH or TH, patients with healing generally experienced improved clinical outcomes and reduced healthcare resource utilization, including fewer hospitalizations and surgeries and improved rates of clinical remission. This was especially true for patients with TH. Conclusions: Mucosal and transmural healing are associated with positive long-term outcomes for adult patients with Crohn’s disease. The adoption of standardized measures and less invasive assessment tools will maximize the benefits of patient monitoring.
- 18 July 2024
- Published by Elsevier in Experimental Hematology
- Vol. 138, 104282
TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells
- 18 July 2024
- Published by Elsevier in Experimental Hematology
- Vol. 138, 104282
TAZ downregulated ANXA1 expression to modulate myeloma cell interactions with bone marrow mesenchymal stromal cells
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S320
PCR45 Advantages of Fixed-Dose Combination (FDC) Products over Loose Dose Combination (LDC) Products: A Systematic Literature Review (SLR)
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S320
PCR45 Advantages of Fixed-Dose Combination (FDC) Products over Loose Dose Combination (LDC) Products: A Systematic Literature Review (SLR)
- Open Access
- 17 March 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (5) , 2051-2081
Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
Introduction Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and UC. Methods Two systematic literature reviews (SLRs) were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE®, Embase®, and Cochrane Library were searched for articles published between January 2011 and October 2021 and limited to non-interventional studies in English language. Congress and bibliographic searches were also conducted. Articles were screened by two independent researchers. Dose escalation patterns were described and summarized considering the regional regulatory label recommendation (in North America [NA] or outside of North America [ONA]). Results Among 3190 CD and 2116 UC articles identified in the Ovid searches, 100 CD and 54 UC studies were included in the SLR, with more studies conducted ONA. Most studies reported an initial maintenance dose pattern aligned with the lower starting dose per local regulatory label; however, several ONA studies (n = 13 out of 14) reported ustekinumab every 8 weeks as starting maintenance pattern in CD. In ONA studies, the median within-guideline escalation rates in CD and UC were 43% in ustekinumab (CD only), 33% and 32% for vedolizumab; 29% and 39% for adalimumab; and 14% and 10% for infliximab. Evidence regarding dose escalation patterns for tofacitinib, certolizumab pegol, and golimumab was limited. Some dose escalation patterns outside of label recommendations were observed including ustekinumab every 8 weeks to every 4 weeks and vedolizumab every 8 weeks to every 6 weeks. Conclusion Dose escalation strategies are widely documented in the literature. The reported dose escalation patterns and escalation rates vary by region and by CD and UC. Most escalation patterns reported were aligned with regulatory recommendations while some reported more diverse or aggressive dose escalation. Prospero Registration CRD42021289251.
- 17 March 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (5) , 2051-2081
Open AccessDose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
Introduction Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and UC. Methods Two systematic literature reviews (SLRs) were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE®, Embase®, and Cochrane Library were searched for articles published between January 2011 and October 2021 and limited to non-interventional studies in English language. Congress and bibliographic searches were also conducted. Articles were screened by two independent researchers. Dose escalation patterns were described and summarized considering the regional regulatory label recommendation (in North America [NA] or outside of North America [ONA]). Results Among 3190 CD and 2116 UC articles identified in the Ovid searches, 100 CD and 54 UC studies were included in the SLR, with more studies conducted ONA. Most studies reported an initial maintenance dose pattern aligned with the lower starting dose per local regulatory label; however, several ONA studies (n = 13 out of 14) reported ustekinumab every 8 weeks as starting maintenance pattern in CD. In ONA studies, the median within-guideline escalation rates in CD and UC were 43% in ustekinumab (CD only), 33% and 32% for vedolizumab; 29% and 39% for adalimumab; and 14% and 10% for infliximab. Evidence regarding dose escalation patterns for tofacitinib, certolizumab pegol, and golimumab was limited. Some dose escalation patterns outside of label recommendations were observed including ustekinumab every 8 weeks to every 4 weeks and vedolizumab every 8 weeks to every 6 weeks. Conclusion Dose escalation strategies are widely documented in the literature. The reported dose escalation patterns and escalation rates vary by region and by CD and UC. Most escalation patterns reported were aligned with regulatory recommendations while some reported more diverse or aggressive dose escalation. Prospero Registration CRD42021289251.
- Open Access
- 1 October 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (23) , 1751-1756
Plain Language Summary of a Fingerprinting Technique to Monitor Blood Cancer
What is this summary about? This is a plain language summary discussing the results of our study published in the journal Nanomedicine. The study describes how to improve the detection of blood can...
- 1 October 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (23) , 1751-1756
Open AccessPlain Language Summary of a Fingerprinting Technique to Monitor Blood Cancer
What is this summary about? This is a plain language summary discussing the results of our study published in the journal Nanomedicine. The study describes how to improve the detection of blood can...
- Open Access
- 22 September 2021
- Published by Taylor & Francis in Nanomedicine
- Vol. 16 (24) , 2175-2188
Nanoparticle Surface-Enhanced Raman Spectroscopy as A Noninvasive, Label-Free Tool to Monitor Hematological Malignancy
Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a poten... Plain Language Summary Cancer patient quality of life is achieved by reassurance from informed doctors using the best clinical tools. Confirming the earliest detection or absence of disease ensures...
- 22 September 2021
- Published by Taylor & Francis in Nanomedicine
- Vol. 16 (24) , 2175-2188
Open AccessNanoparticle Surface-Enhanced Raman Spectroscopy as A Noninvasive, Label-Free Tool to Monitor Hematological Malignancy
Aim: Monitoring minimal residual disease remains a challenge to the effective medical management of hematological malignancies; yet surface-enhanced Raman spectroscopy (SERS) has emerged as a poten... Plain Language Summary Cancer patient quality of life is achieved by reassurance from informed doctors using the best clinical tools. Confirming the earliest detection or absence of disease ensures...
- Open Access
- 19 November 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (22) , 3613-3625
TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC
Key Points: Expression of Hippo component TAZ is downregulated in MM through hypermethylation. TAZ reexpression, exogenously or pharmacologically, causes apoptosis and enhances sensitivity to anti-MM therapies by downregulating MYC.
- 19 November 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (22) , 3613-3625
Open AccessTAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC
Key Points: Expression of Hippo component TAZ is downregulated in MM through hypermethylation. TAZ reexpression, exogenously or pharmacologically, causes apoptosis and enhances sensitivity to anti-MM therapies by downregulating MYC.
- 1 August 2016
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 36 (15) , 2078-2088
Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis
Calpain is an intracellular Ca2+ regulated protease system whose substrates include proteins involved in proliferation, survival, migration, invasion and sensitivity to therapeutic drugs. Genetic disruption of calpain attenuated the tumorigenic potential of breast cancer cells and hypersensitized cells to 17AAG, an inhibitor of the molecular chaperone HSP90. Calpain-1 or -2 over-expression rendered cells resistant to 17AAG, whereas down-regulating or inhibiting calpain-1/2 led to increased cell death in multiple breast cancer cell lines, including models of HER2+ (SKBR3) and triple negative basal-like (MDA-MB-231) breast cancer. In an MDA-MB-231 orthotopic xenograft model, calpain knockdown or 17AAG treatment independently attenuated tumor growth and metastasis while the combination was most effective. Calpain knockdown was associated with increased 17AAG-induced degradation of HSP90 clients cyclin D1 and AKT and MRP2, which correlated with increased expression of anti-mitogenic p27KIP1 and pro-apoptotic BIM proteins. Like other therapeutics, 17AAG can be effluxed by specific ABC transporters. Calpain expression positively correlated with expression of Pgp in mouse embryonic fibroblasts. Importantly, we show that calpain affects ABC transporter function and efflux of clinically relevant doxorubicin. These observations provide compelling rationale for exploring the combination of calpain inhibition with new or existing cancer therapeutics.
- 1 August 2016
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 36 (15) , 2078-2088
Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis
Calpain is an intracellular Ca2+ regulated protease system whose substrates include proteins involved in proliferation, survival, migration, invasion and sensitivity to therapeutic drugs. Genetic disruption of calpain attenuated the tumorigenic potential of breast cancer cells and hypersensitized cells to 17AAG, an inhibitor of the molecular chaperone HSP90. Calpain-1 or -2 over-expression rendered cells resistant to 17AAG, whereas down-regulating or inhibiting calpain-1/2 led to increased cell death in multiple breast cancer cell lines, including models of HER2+ (SKBR3) and triple negative basal-like (MDA-MB-231) breast cancer. In an MDA-MB-231 orthotopic xenograft model, calpain knockdown or 17AAG treatment independently attenuated tumor growth and metastasis while the combination was most effective. Calpain knockdown was associated with increased 17AAG-induced degradation of HSP90 clients cyclin D1 and AKT and MRP2, which correlated with increased expression of anti-mitogenic p27KIP1 and pro-apoptotic BIM proteins. Like other therapeutics, 17AAG can be effluxed by specific ABC transporters. Calpain expression positively correlated with expression of Pgp in mouse embryonic fibroblasts. Importantly, we show that calpain affects ABC transporter function and efflux of clinically relevant doxorubicin. These observations provide compelling rationale for exploring the combination of calpain inhibition with new or existing cancer therapeutics.